Translational Research/Biomarkers 2022
DOI: 10.1136/ijgc-2022-esgo.872
|View full text |Cite
|
Sign up to set email alerts
|

2022-RA-807-ESGO MLH1 promoter methylation analysis in patients with endometrial cancer stage I-II

Abstract: Conclusion Expression of TROP-2 in cervical cancer is associated with increased levels of intratumoral TILs, indicating the potential therapeutic target for TROP-2 targeted antibody-drug conjugate alone or in combination with immune checkpoint inhibitors.

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles